Drägerwerk AG & Co. KGaA Stock (DE0005550636): Analyst coverage dries up as shares stabilize above EUR 90

With no fresh analyst ratings in the past six months, Drägerwerk AG & Co. KGaA remains a stock in focus for valuation-driven investors as the German medtech and safety specialist trades around EUR 91.70 on Xetra.

By AD HOC NEWS - Companies & Analysis Desk Team | June 10, 2026

The stock of Drägerwerk AG & Co. KGaA is back on the radar of valuation-focused investors as trading has calmed down and formal analyst coverage has gone quiet in recent months. On the Xetra market, the preferred share recently changed hands at about EUR 91.70 as of May 22, 2026, 09:50 CET, implying a marginal day-on-day move of -0.43 percent according to data from comdirect. With no new target price or rating updates published in the last six months, the stock effectively trades without fresh broker guidance, leaving market participants to rely more heavily on fundamentals and company disclosures. The Lübeck-based group, known for medical and safety technology used in hospitals, emergency services, industry and the public sector, remains a key mid-cap name in the German healthcare equipment space.

Analyst coverage gap: what the latest data shows

For Drägerwerk, one of the more striking datapoints for investors is the lack of recent analyst action documented in major data aggregators. A current overview of target prices and analyst estimates for the stock shows that there have been no published analyst opinions in the last six months. This absence of updated recommendations or formal rating changes stands in contrast to periods when Drägerwerk drew more frequent broker commentary around earnings seasons or during phases of sharper share price swings.

The same dataset lists a current share price level of roughly EUR 72.60 for Drägerwerk in one trading venue snapshot, together with a stated market capitalization of about EUR 1.53 billion, a price-earnings ratio around 7.6 and a dividend yield close to 3.9 percent, illustrating that the stock is still actively followed in terms of basic valuation metrics even if sell-side brokers are not issuing new reports. The symbol DGWPF is cited for trading in certain international contexts, underlining that the company is also accessible for investors outside Germany through alternative listings, although the primary and most liquid market remains Xetra with trading currency in euro. For U.S.-based retail investors, exposure typically runs via international trading platforms that route orders into European markets or through over-the-counter instruments that mirror the German line.

Investors monitoring ownership structures will note that Drägerwerk remains tightly held. Recent shareholder composition data attributes approximately 71.62 percent of the capital to the Draeger family-related holding, while free float accounts for about 16.64 percent. Additional institutional shareholders include Brandes Investment Partners with several disclosed stakes, Norges Bank Investment Management and other asset managers with smaller single-digit or sub-one-percent positions. This concentrated ownership profile can contribute to lower daily free-float liquidity and potentially amplifies price moves in response to company-specific news, a factor that investors sometimes weigh when comparing Drägerwerk to larger, more widely held European medtech peers.

The latest trading snapshot on comdirect for the preferred share shows a bid of EUR 91.60 and an ask of EUR 91.90 at 09:50 CET on May 22, 2026, implying a relatively tight spread of around 0.33 percent, with 770 shares traded and a turnover volume near EUR 71,182 on that day. For intraday context, the same data lists an opening price of EUR 92.60, a session high of EUR 93.50 and a previous close of EUR 92.10, confirming that, at least on that reference date, Drägerwerk traded within a narrow band and did not exhibit extreme volatility. That picture fits with other recent observations that the share has stabilized after more turbulent phases in the prior year, when the price moved between roughly EUR 45 and EUR 50 over certain stretches before rallying significantly afterward.

One driver behind the longer-term upswing was highlighted in an InvestingPro fair value analysis from 2024. At that time, Drägerwerk was flagged as undervalued around EUR 44.00, with the platform's fair value indication pointing to a substantially higher intrinsic value. Since that signal, the stock price has advanced markedly, at one point rising by around 64 percent relative to that April 2024 reference level, as the market reassessed the company's earnings power after a series of stronger quarters. While such quantitative fair value tools are not the same as traditional sell-side research, they have in practice partly filled the information gap for some investors during intervals when broker coverage was thin.

Beyond the trading metrics, Drägerwerk's business profile remains firmly anchored in two core segments: medical technology and safety technology. Company and third-party descriptions alike emphasize that Drägerwerk develops, produces and sells devices and systems such as ventilators, anesthesia workstations, patient monitoring equipment and related IT solutions for hospitals, as well as personal protective equipment, gas detection systems and other safety solutions for industrial customers and public-sector clients. The company serves customers worldwide, with core markets in Europe and other international regions where advanced hospital infrastructure and industrial safety standards support demand for high-specification equipment. Revenue is underpinned by both capital equipment sales and recurring income from services, consumables and maintenance contracts associated with installed base equipment.

Operationally, Drägerwerk continues to recruit for specialist roles in areas such as transportation management, production and human resources, which indicates an ongoing focus on logistics efficiency, manufacturing capacity and talent acquisition. Recent job advertisements for positions like Head of Transportation Management and various HR and production roles in Lübeck and surrounding regions suggest that the company is investing in its supply chain and workforce to support its global activities in medical and safety technology. While such personnel postings do not directly translate into near-term earnings revisions, they offer additional context on how Drägerwerk is positioning its organization for future demand, particularly in critical infrastructure and healthcare markets.

With respect to governance and location, Drägerwerk maintains its corporate headquarters in Lübeck, Germany, at Moislinger Allee, where its central administration, engineering and parts of its production footprint are based. Contact information from corporate profiles lists a general company phone number, fax and email address, and prominently features the official corporate website, where investors can access financial reports, ad hoc disclosures and information about upcoming events such as annual general meetings and quarterly statements. The investor relations section of the company website offers presentations, financial data archives and regulatory filings designed to support analysts, institutional investors and retail shareholders in evaluating the group's performance and strategy.

For U.S. investors, one aspect to keep in mind is that Drägerwerk reports its financials under European standards and trades primarily in euro on European exchanges, introducing both accounting and currency translation considerations when comparing its valuation to U.S.-listed medtech or safety peers. Basic metrics such as the stated dividend yield near 3.9 percent and a mid-single-digit earnings multiple, as cited in recent data, are calculated in euro and need to be translated into U.S. dollars where relevant for portfolio allocation decisions. Moreover, the relatively modest free float and family-controlled structure mean that Drägerwerk's stock behavior can differ from that of large-cap U.S. healthcare names with broader analyst coverage and more frequent earnings commentary.

As long as no new broker ratings or target price updates are published, market participants are likely to rely on upcoming financial reports, company guidance and sector trends in medical and safety technology to refine their view of Drägerwerk's risk-return profile. In a context of limited fresh analyst input, attention tends to shift toward fundamentals such as revenue growth by segment, margin development, cash flow generation and capital allocation policies, including dividends and potential share buybacks. How Drägerwerk navigates demand cycles in hospital equipment, inflationary cost pressures and investment needs in production and logistics will remain key parameters for investors monitoring the stock as it trades in the low-90-euro range on Xetra.

Drägerwerk key facts for investors

• Name: Drägerwerk AG & Co. KGaA
• Industry: Medical technology and safety technology
• Headquarters: Lübeck, Germany
• Core markets: Hospitals, emergency services, industrial customers and public-sector clients worldwide
• Revenue drivers: Medical ventilation and anesthesia systems, patient monitoring, gas detection and safety systems, plus related services and consumables
• Listing: Xetra (Germany), preferred share; additional international trading under symbol DGWPF where available
• Trading currency: Euro (EUR)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.